The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Safety of antisense oligonucleotide and siRNA-based therapeutics
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans
Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., & Mello, C. C. (1998) · Nature · doi:10.1038/35888 · Cited by 15,429
Safety and efficacy of RNAi therapy for transthyretin amyloidosis
Coelho, T., Adams, D., Silva, A., Lozeron, P., Hawkins, P. N., Mant, T., Perez, J., Chiesa, J., Warrington, S., Tranter, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208760 · Cited by 971
Knocking down disease: a progress report on siRNA therapeutics
Wittrup, A., & Lieberman, J. (2015) · Nature Reviews Genetics · doi:10.1038/nrg3978 · Cited by 804
Emerging roles for platelets as immune and inflammatory cells
Morrell, C. N., Aggrey, A. A., Chapman, L. M., & Modjeski, K. L. (2014) · Blood · doi:10.1182/blood-2013-11-462432 · Cited by 735
Prakash, T. P., Graham, M. J., Yu, J., Carty, R., Low, A., Chappell, A., Schmidt, K., Zhao, C., Aghajan, M., Murray, H. F., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku531 · Cited by 610
Design of Noninflammatory Synthetic siRNA Mediating Potent Gene Silencing in Vivo
Judge, A. D., Bola, G., Lee, A. C. H., & MacLachlan, I. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2005.11.002 · Cited by 571
Silencing disease genes in the laboratory and the clinic
Watts, J. K., & Corey, D. R. (2012) · The Journal of Pathology · doi:10.1002/path.2993 · Cited by 470
Efficient Reduction of Target RNAs by Small Interfering RNA and RNase H-dependent Antisense Agents
Vickers, T. A., Koo, S., Bennett, C. F., Crooke, S. T., Dean, N. M., & Baker, B. F. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210326200 · Cited by 461
Preclinical and clinical development of siRNA-based therapeutics
Ozcan, G., Ozpolat, B., Coleman, R. L., Sood, A. K., & Lopez-Berestein, G. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.01.007 · Cited by 449
Szebeni, J., Muggia, F., Gabizon, A., & Barenholz, Y. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.06.017 · Cited by 423
Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo
Bertrand, J.-R., Pottier, M., Vekris, A., Opolon, P., Maksimenko, A., & Malvy, C. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)02013-2 · Cited by 400
Frazier, K. S. (2015) · Toxicologic Pathology · doi:10.1177/0192623314551840 · Cited by 334
Sekijima, Y. (2015) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-308724 · Cited by 332
A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis
Tefferi, A., Lasho, T. L., Begna, K. H., Patnaik, M. M., Zblewski, D. L., Finke, C. M., Laborde, R. R., Wassie, E., Schimek, L., Hanson, C. A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1310523 · Cited by 325
Suhr, O. B., Coelho, T., Buades, J., Pouget, J., Conceicao, I., Berk, J., Schmidt, H., Waddington-Cruz, M., Campistol, J. M., Bettencourt, B. R., et al. (2015) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-015-0326-6 · Cited by 321
Kretschmer-Kazemi Far, R. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg649 · Cited by 291
Going beyond the liver: progress and challenges of targeted delivery of siRNA therapeutics
Lorenzer, C., Dirin, M., Winkler, A.-M., Baumann, V., & Winkler, J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.02.003 · Cited by 284
Grunweller, A. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg409 · Cited by 269
Matsuda, S., Keiser, K., Nair, J. K., Charisse, K., Manoharan, R. M., Kretschmer, P., Peng, C. G., V. Kel’in, A., Kandasamy, P., Willoughby, J. L. S., et al. (2015) · ACS Chemical Biology · doi:10.1021/cb501028c · Cited by 221
Lipid-Based Nanocarriers for RNA Delivery
Xue, H., Guo, P., Wen, W.-C., & Wong, H. (2015) · Current Pharmaceutical Design · doi:10.2174/1381612821666150531164540 · Cited by 201
siRNA target site secondary structure predictions using local stable substructures
Heale, B. S. E. (2005) · Nucleic Acids Research · doi:10.1093/nar/gni026 · Cited by 176
Jaax, M. E., Krauel, K., Marschall, T., Brandt, S., Gansler, J., Fürll, B., Appel, B., Fischer, S., Block, S., Helm, C. A., et al. (2013) · Blood · doi:10.1182/blood-2013-01-478966 · Cited by 162
Ackermann, E. J., Guo, S., Benson, M. D., Booten, S. L., Freier, S., Hughes, S. G., Kim, T., Kwoh, T. J., Matson, J. E., Norris, D., et al. (2016) · Amyloid · doi:10.1080/13506129.2016.1191458 · Cited by 153
Henry, S. P., Beattie, G., Yeh, G., Chappel, A., Giclas, P. C., Mortari, A., Jagels, M. A., Kornbrust, D. J., & Levin, A. A. (2002) · International Immunopharmacology · doi:10.1016/s1567-5769(02)00142-x · Cited by 151
Wu, S. Y., Yang, X., Gharpure, K. M., Hatakeyama, H., Egli, M., McGuire, M. H., Nagaraja, A. S., Miyake, T. M., Rupaimoole, R., Pecot, C. V., et al. (2014) · Nature Communications · doi:10.1038/ncomms4459 · Cited by 146
Gene and cell therapy : therapeutic mechanisms and strategies
Templeton, N. S. (2004) · Cited by 142
Hong, D. S., Kurzrock, R., Oh, Y. W., Wheler, J. J., Naing, A., Brail, L. H., Callies, S., André, V., KADAM, S. K., Nasir, A., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0430 · Cited by 140
Ackermann, E. J., Guo, S., Booten, S. L., Alvarado, L., Benson, M. D., Hughes, S. G., & Monia, B. P. (2012) · Amyloid · doi:10.3109/13506129.2012.673140 · Cited by 139
“Antisense Drug Technology. Principles, Strategies, and Applications”
Lee, G. (2002) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(02)00090-5 · Cited by 135
Crooke, S. T., Baker, B. F., Kwoh, T. J., Cheng, W., Schulz, D. J., Xia, S., Salgado, N. R., Bui, H., Hart, C. E., Burel, S. A., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.136 · Cited by 133
Prakash, T. P., Yu, J., Migawa, M. T., Kinberger, G. A., Wan, W. B., Østergaard, M. E., Carty, R. L., Vasquez, G., Low, A., Chappell, A. E., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01948 · Cited by 132
Mansoor, M., & Melendez, A. J. (2008) · Gene Regulation and Systems Biology · doi:10.4137/grsb.s418 · Cited by 130
Sewell, K. L., Geary, R. S., Baker, B. F., Glover, J., Mant, T., Yu, R. Z., Tami, J. A., & Dorr, F. A. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.036749 · Cited by 121
Phosphorothioate backbone modifications of nucleotide-based drugs are potent platelet activators
Flierl, U., Nero, T. L., Lim, B., Arthur, J. F., Yao, Y., Jung, S. M., Gitz, E., Pollitt, A. Y., Zaldivia, M. T. K., Jandrot-Perrus, M., et al. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20140391 · Cited by 114
Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis
Butler, J. S., Chan, A., Costelha, S., Fishman, S., Willoughby, J. L. S., Borland, T. D., Milstein, S., Foster, D. J., Gonçalves, P., Chen, Q., et al. (2016) · Amyloid · doi:10.3109/13506129.2016.1160882 · Cited by 113
Salloum, R., Hummel, T. R., Kumar, S. S., Dorris, K. M. O., Li, S., Lin, T., Daryani, V. M., Stewart, C. F., Miles, L., Poussaint, T. Y., et al. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2189-7 · Cited by 107
Disposition and Pharmacology of a GalNAc3-conjugated ASO Targeting Human Lipoprotein (a) in Mice
Yu, R. Z., Graham, M. J., Post, N. M., Riney, S., Zanardi, T. A., Hall, S., Burkey, J., Shemesh, C. S., Prakash, T. P., Seth, P. P., et al. (2016) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2016.26 · Cited by 97
siRNA-optimized Modifications for Enhanced In Vivo Activity
Kenski, D. M., Butora, G., Willingham, A. T., Cooper, A. J., Fu, W., Qi, N. L., Soriano, F., Davies, I. W., & Flanagan, W. M. (2012) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2011.4 · Cited by 95
Hartmann, G., Krug, A., Waller-Fontaine, K., & Endres, S. (1996) · Molecular Medicine · doi:10.1007/bf03401902 · Cited by 89
Coudert, B. P., Anthoney, A., Fiedler, W., Droz, J., Dieras, V. C., Borner, M., Smyth, J. F., Morant, R., de Vries, M. J., Roelvink, M., et al. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00286-6 · Cited by 83
Henry, S. P., Geary, R. S., Yu, R. Z., & Levin, A. A. (2001) · PubMed · Cited by 79
Tao, W., Mao, X., Davide, J. P., Ng, B., Cai, M., Burke, P. A., Sachs, A. B., & Sepp‐Lorenzino, L. (2010) · Molecular Therapy · doi:10.1038/mt.2010.282 · Cited by 73
Phosphorothioate Oligonucleotides: Effectiveness and Toxicity
Iannitti, T., Morales‐Medina, J. C., & Palmieri, B. (2014) · Current Drug Targets · doi:10.2174/1389450115666140321100304 · Cited by 73
Oligodeoxynucleotide Studies in Primates: Antisense and Immune Stimulatory Indications
Farman, C. A., & Kornbrust, D. J. (2003) · Toxicologic Pathology · doi:10.1080/01926230390174995 · Cited by 61
CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS
Limmroth, V., Barkhof, F., Desem, N., Diamond, M. P., Tachas, G., & For the ATL1102 Study Group (2014) · Neurology · doi:10.1212/wnl.0000000000000926 · Cited by 58
Engelhardt, J. A., Fant, P., Guionaud, S., Henry, S. P., Leach, M. W., Louden, C. S., Scicchitano, M. S., Weaver, J. L., Zabka, T. S., & Frazier, K. S. (2015) · Toxicologic Pathology · doi:10.1177/0192623315570341 · Cited by 53
Obici, L. P., & Merlini, G. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.922541 · Cited by 53
Yu, R. Z., Grundy, J. S., Henry, S. P., Kim, T., Norris, D. A., Burkey, J., Wang, Y., Vick, A., & Geary, R. S. (2015) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2014.69 · Cited by 50
Shen, L., Frazer‐Abel, A. A., Reynolds, P. R., Giclas, P. C., Chappell, A. E., Pangburn, M. K., Younis, H. S., & Henry, S. P. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.219378 · Cited by 49
Hebb, M. O., & Robertson, H. A. (1997) · Molecular Brain Research · doi:10.1016/s0169-328x(97)00048-x · Cited by 48
Therapeutic Oligonucleotides Targeting Liver Disease: TTR Amyloidosis
Niemietz, C., Chandhok, G., & Schmidt, H. (2015) · Molecules · doi:10.3390/molecules201017944 · Cited by 37
Toxicologic Properties of 2-O-Methoxyethyl Chimeric Antisense Inhibitors in Animals and Man
Henry, S. P., Kim, T., Kramer-Stickland, K., Zanardi, T. A., Fey, R. A., & Levin, A. A. (2007) · CRC Press eBooks · doi:10.1201/9780849387951-20 · Cited by 37
Kwoh, T. J. (2007) · CRC Press eBooks · doi:10.1201/9780849387951-21 · Cited by 19
Toxicology of Oligonucleotide Therapeutics and Understanding the Relevance of the Toxicities
Levin, A. A., & Henry, S. P. (2010) · Wiley eBooks · doi:10.1002/9780470571224.pse183 · Cited by 11
Gillmore, J. D., Falk, R. H., Maurer, M. S., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(15)60971-8 · Cited by 7
(2001) · doi:10.1002/1439-7633(20010401)2:4<239::aid-cbic239>3.0.co;2-r
Cited by
The JAK/STAT signaling pathway: from bench to clinic
Hu, X., li, J., Fu, M., Zhao, X., & Wang, W. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00791-1 · Cited by 2,633
Advances in the delivery of RNA therapeutics: from concept to clinical reality
Kaczmarek, J. C., Kowalski, P. S., & Anderson, D. G. (2017) · Genome Medicine · doi:10.1186/s13073-017-0450-0 · Cited by 656
“Despite recent setbacks surrounding withdrawal of Alnylams’s siRNA–GalNac conjugate [160] and Curevac’s first mRNA vaccine [100] from clinical trials, nucleic acid-based therapeutics continue to progress, as highlighted by the approval of four ASOs by the FDA [159] and more RNA candidate drugs with improved chemical m…”
BackgroundChemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs
Shen, X., & Corey, D. R. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1239 · Cited by 632
Wolfram, J., & Ferrari, M. (2019) · Nano Today · doi:10.1016/j.nantod.2019.02.005 · Cited by 436
Täubel, J., Hauke, W., Rump, S., Viereck, J., Batkai, S., Poetzsch, J., Rode, L., Weigt, H., Genschel, C., Lorch, U., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa898 · Cited by 393
Metadata
- Authors
- Chi, X., Gatti, P., & Papoian, T.
- Venue
- Drug Discovery Today
- Publisher
- Elsevier BV
- Published
- 2017-05
- Volume
- 22
- Issue
- 5
- Pages
- 823-833
- ISSN
- 1359-6446 (ISSN-L)
- OpenAlex
- W2583555090
- Cited by
- 280
- References
- 56
- FWCI
- 10.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.